Biopolym. Cell. 2017; 33(6):453-462.
http://dx.doi.org/10.7124/bc.000968
Viruses and Cell
In vitro and in vivo investigations on anti-influenza effect of adamantyl (alkyl, cycloalkyl) derivatives of aminopropanol-2
1Voloshchuk O. M., 2Korotkiy Y. V., 3Rybalko S. L., 3Starosila D. B., 1Shirobokov V. P.
  1. Bogomolets National Medical University
    13, Shevchenko Blvd., Kyiv, Ukraine, 01601
  2. Institute of organic chemistry NAS of Ukraine
    5, Murmanska Str., Kyiv, Ukraine, 02660
  3. Gromashevsky L. V. Institute of Epidemiology and Infection Diseases, NAMS of Ukraine
    5, Amosova Str., Kyiv, Ukraine, 03038

Abstract

Aim. To establish anti-influenza activities for 8 compounds of adamantyl (alkyl, cycloalkyl) de-rivatives of aminopropanol-2 in vitro and in vivo investigations. Methods. The antiviral action of compounds was determined in vitro by reduction of infectious titer of the influenza virus in the Madin-Darby Canine Kidney (MDCK) cell culture and in vivo on the model of influenza pneu-monia in mice. Results. Three of eight studied compounds inhibit the reproduction of the influ-enza virus strain A/FM/1/47(H1N1) by more than 2 lg ID50 in the concentration range from < 0.39 µg/ml (the compounds 30 and 33) to 1.56 µg/ml (the compound 5), their chemotherapeutic indices are 256 and 16, respectively. The experiments in vivo showed that in prophylactic scheme the efficiency index (EI) of the compounds 5 and 30 is 60 %; in therapeutic scheme EI of the compounds 5 and 33 is 100 % that is two times higher, than for rimantadine. Conclusions. High chemotherapeutic indices of the compounds 30, 33 and their ability to suppress the influenza virus reproduction in the MDCK cell culture by more than 2 lg ID50 indicate the anti-influenza activity of these compounds. It has been also confirmed by in vivo experiment.
Keywords: influenza virus, adamantyl (alkyl, cycloalkyl) derivatives of aminopropanol-2, antiviral activity
Full text: (PDF, in English)

References

[1] Markovic IG. Grinevich ATh. The analysis of morbidity of influenza of population of Ukraine for 2009-2013. Ukraine. The health of the nation. 2013; 2: 118-24.
[2] Pauwels R. Aspects of successful drug discovery and development. Antiviral Res. 2006;71(2-3):77-89.
[3] Davies WL, Grunert RR, Haff RF, Mcgahen JW, Neumayer EM, Paulshock M, Watts JC, Wood TR, Hermann EC, Hoffmann CE. Antiviral activity of 1-adamantanamine (amantadine). Science. 1964;144(3620):862-3.
[4] Liu J, Obando D, Liao V, Lifa T, Codd R. The many faces of the adamantyl group in drug design. Eur J Med Chem. 2011;46(6):1949-63.
[5] Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev. 2013;113(5):3516-604.
[6] Rosenthal KS, Sokol MS, Ingram RL, Subramanian R, Fort RC. Tromantadine: inhibitor of early and late events in herpes simplex virus replication. Antimicrob Agents Chemother. 1982;22(6):1031-6. PubMed Central
[7] Tsounda A, Maassab H, Cocron K, Evelant W. Antiviral activity of a α -methyl-1-adamantane methylamine hydrochloride. Antimic. Agents. Chemother. New Work, 1965; P. 553-560.
[8] Akhrem I, Orlinkov A. Polyhalomethanes combined with Lewis acids in alkane chemistry. Chem Rev. 2007;107(5):2037-79.
[9] Schreiner PR, Fokin AA. Selective alkane C-H-bond functionalizations utilizing oxidative single-electron transfer and organocatalysis. Chem Rec. 2004;3(5):247-57.
[10] Fokin AA, Schreiner PR. Metal-free, selective alkane functionalizations. Adv Synth Catal. 2003; 345(9-10): 1035–52.
[11] Schreiner PR, Lauenstein O, Butova ED, Gunchenko PA, Kolomitsin IV, Wittkopp A, Feder G, Fokin AA. Selective radical reactions in multiphase systems: phase-transfer halogenations of alkanes. Chemistry. 2001;7(23):4996-5003.
[12] Saunders M, Jiménez-Vázquez HA. Recent studies of carbocations. Chem Rev. 1991; 91(3):375–97.
[13] Fleck C, Franzmann E, Claes D, Rickert A, Maison W. Synthesis of functionalized adamantane derivatives: (3 + 1)-scaffolds for applications in medicinal and material chemistry. Synthesis. 2013; 45(11): 1452–61.
[14] Shvekhgeimer MGA. Adamantane derivatives containing heterocyclic substituents in the bridgehead positions. Synthesis and properties. Russ Chem Rev. 1996; 65: 555–98.
[15] Korotkii YV, Vrynchanu NA, Dronova ML, Suvorova ZS, Smertenko OA. Synthesis, antibacterial and antifugul activity of derivatives of 1[4-(1,1,3,3-tetrametylbutyl) phenoxy-3]-dialkylamino-2-propanol quaternary salts. Farm Zh 2015; 1; 56-62.
[16] Shcherbinsky AM, Dyachenko N, Rybalko SL. et al. Study of the antiviral action of potential medical remedies. Method. recommendations. Kyiv, 2001: 528.
[17] Volyansky Yul, Gritsenko IS, Shirobokov VP, Dubinina N. In: Study of the specific activity of antimicrobial drugs. Method recommend. Kyiv, 2004: 38.
[18] Lamoureux G, Artavia G. Use of the adamantane structure in medicinal chemistry. Curr Med Chem. 2010;17(26):2967-78.
[19] Shokova EA, Kovalev VV. Adamantane functionalization. Synthesis of polyfunctional derivatives with various substituents in bridgehead positions. Russ J Org Chem. 2012; 48(8):1007-40.
[20] Shen Z, Lou K, Wang W. New small-molecule drug design strategies for fighting resistant influenza A. Acta Pharm Sin B. 2015;5(5):419-30.
[21] Garashchenko TI, Mezenceva MV. Clinic-immunological basis homeopathic drugs for prophylactics and therapy flu and ORVI. Rus Med J. 2005;13(21):1432-1437.